DOCSLIB.ORG

Cyclic Nucleotide Phosphodiesterases (Pdes) in Smooth Muscle: Expression, Function and Mechanism

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cyclic Nucleotide Phosphodiesterases (Pdes) in Smooth Muscle: Expression, Function and Mechanism Joint Thesis Supervision between UNIVERSITÉ PARIS-SUD DOCTORAL SCHOOL: INNOVATION THÉRAPEUTIQUE: DU FONDAMENTAL A L’APPLIQUÉ PÔ LE: PHYSIOPATHOLOGIE MOLECULAIRE ET CELLULAIRE DISCIPLINE: PHYSIOPATHOLOGIE MOLECULAIRE ET CELLULAIRE & INSTITUTE OF BIOPHYSICS (CHINESE ACADEMY OF SCIENCES) YEAR 2012 - 2013 SÉRIE DOCTORAT N° DOCTORAL THESIS defended on November 20th, 2012 by Kui ZHAI Cyclic Nucleotide Phosphodiesterases (PDEs) in Smooth Muscle: Expression, Function and Mechanism Director of thesis: Véronique LEBLAIS Professeur des Universités (Université Paris-Sud, France) Co-director of thesis: Guangju JI Professeur (Chinese Academy of Science, Beijing, Chine) Composition of the jury: President and reviewer: Qing-Hua LIU Professeur (South-Central University for Nationalities, Wuhan, Chine) Reviewer: Claire LUGNIER DR émérite CNRS (Université de Strasbourg) Examiners: Rodolphe FISCHMEISTER DR Inserm (Université Paris-Sud, France) Zengqiang YUAN Professeur (Chinese Academy of Science, Beijing, Chine) Acknowledgements Acknowledgements This thesis was based on experimental work done in INSERM UMR-S 769, LabEx LERMIT, Faculté de Pharmacie, Université Paris-Sud and in National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences. In 2008, I was fortunate to receive a doctoral grant from French Embassy which I am truly grateful to. Additional support was provided by Université Paris-Sud and Institute of Biophysics, which are highly appreciable. My deepest gratitude goes firstly and foremost to my directors Prof. Véronique LEBLAIS and Prof. Guangju JI. Their professional guidance, constant encouragement and support kept me all the way on track during my scientific research. I address my special thanks to them for their supervision and guidance over the past years. I would also express heartfelt gratitude to Dr. Rodolphe FISCHMEISTER, Director of Inserm UMR-S 769, for giving me the opportunity to work in his lab, sharing his endless knowledge in physiology and pharmacology, and creating a pleasant working atmosphere. I would like to thank all my wonderful colleagues for teaching me techniques, offering experimental tips. I sincerely thank Fabien HUBERT for his help in all experiments. I would like to express gratitude to Dr. Grégoire VANDECASTEELE, Dr. Jérôme LEROY and Patrick LECHÈNE for their help on FRET and path clamp experiments; to Valérie NICOLAS for her help on confocal microscope; to Yassine SASSI on cell isolation and culture; to Delphine MIKA, Françoise BOUSSAC, Cristina MOLINA-ESPINOSA, Zeineb HAJ SLIMANE, Philippe MATEO, Julia SCHITTL, Audrey VARIN, Sophie SEURON, Yanyun WU, Congyan PAN, Bin WEI, Xu ZHANG, Lin MIAO, Yan CHANG, Qi YUAN, Yingxiao CHEN, Yinglong TANG, Lei GU and Zhiguang YANG for their all kind help. It gave me many pleasures to work with them. I sincerely thank Dominique FORTIN for her help. It is my great pleasure to spend Christmas with your family and to visit Royan. I am also grateful to Jérôme Acknowledgements PIQUEREAU and Stéphanie RIMBAUD for giving me a chance to visit their beautiful hometown. Special thanks to my friends Jinguo WANG, Sibo LI, Dejiu ZHANG, Xiaoli TIAN and Lin XIA for their help and encouragements. Last but not least, I am especially indebted to my beloved parents and wife for everything they have done for me. Without their love and encourage, I would never have the chance to finish the thesis. Kui ZHAI Beijing, 2012.10 Index Index Index ........................................................................................................... I List of figures .......................................................................................... IV List of tables.............................................................................................. V Glossary and abbreviations ................................................................... VI 1 Introduction ............................................................................................ 1 1.1 Physiology of the smooth muscle ................................................................... 2 1.1.1 Characteristics of the smooth muscle cells............................................................... 2 1.1.2 Cardiovascular system ............................................................................................. 5 1.1.2.1 Overview ....................................................................................................... 5 1.1.2.2 Morphology of vascular smooth muscle (VSM) ........................................... 5 1.1.2.3 Sympathetic innervation ................................................................................ 6 1.1.3 Lower urinary tract ................................................................................................... 7 1.1.3.1 Overview ....................................................................................................... 7 1.1.3.2 Morphology of urinary bladder ..................................................................... 8 1.1.3.3 Spontaneous activity of the bladder .............................................................. 9 1.1.4 Excitation-contraction-coupling (ECC) in the SM ................................................. 11 1.1.4.1 Mechanisms of contraction in the SMC ...................................................... 11 1.1.4.2 The electromechanical coupling .................................................................. 13 1.1.4.3 The pharmacomechanical coupling ............................................................. 13 1.2 The cAMP/β-adrenergic signaling pathway ............................................... 15 1.2.1 β-ARs ..................................................................................................................... 16 1.2.2 G protein ................................................................................................................ 16 1.2.3 Adenylyl cyclase (AC) ........................................................................................... 18 1.2.4 cAMP targets .......................................................................................................... 18 1.2.4.1 PKA ............................................................................................................. 18 1.2.4.2 Epac ............................................................................................................. 20 1.2.4.3 Cyclic nucleotide-activated ion channels .................................................... 20 1.2.5 Mechanisms of cyclic nucleotide-induced relaxation ............................................ 22 2+ 1.2.5.1 Cytosolic Ca concentration modulation in the SMC ................................ 22 I Index 1.2.5.2 Hyperpolarization of the SMC .................................................................... 25 1.2.5.3 Decrease in MLC20 phosphorylation.......................................................... 27 1.3 PDEs family ................................................................................................... 29 1.3.1 PDE1 ...................................................................................................................... 30 1.3.2 PDE2 ...................................................................................................................... 33 1.3.3 PDE3 ...................................................................................................................... 36 1.3.4 PDE4 ...................................................................................................................... 39 1.3.5 PDE5 ...................................................................................................................... 42 1.3.6 PDE6 ...................................................................................................................... 44 1.3.7 PDE7 ...................................................................................................................... 45 1.3.8 PDE8 ...................................................................................................................... 46 1.3.9 PDE9 ...................................................................................................................... 47 1.3.10 PDE10 .................................................................................................................. 48 1.3.11 PDE11 .................................................................................................................. 49 1.4 Cyclic AMP compartmentation ................................................................... 50 1.4.1 Overview ................................................................................................................ 50 1.4.2 Innovative methods for subcellular compartmentation analysis ............................ 52 1.4.3 Role of PDEs in cAMP compartmentation ............................................................ 54 1.4.3.1 PDEs and cAMP compartmentation in cardiac myocyte ............................ 54 1.4.3.2 cAMP compartmentation in SMC ............................................................... 58 2 Objectives of the thesis ........................................................................ 60 3 Materials and methods ........................................................................ 61 3.1 Materials ........................................................................................................ 61 3.1.1 Drugs and reagents ................................................................................................
Load more

Recommended publications
  • Multimodal Treatment Strategies in Huntington's Disease
    Review Article More Information *Address for Correspondence: Rajib Dutta, MD, Neurology, India, Multimodal treatment strategies in Email: [email protected] Submitted: June 23, 2021 Huntington’s disease Approved: July 12, 2021 Published: July 15, 2021 Rajib Dutta* How to cite this article: Dutta R. Multimodal treatment strategies in Huntington’s disease. MD J Neurosci Neurol Disord. 2021; 5: 072-082. DOI: 10.29328/journal.jnnd.1001054 Abstract ORCiD: orcid.org/0000-0002-6129-1038 Copyright: © 2021 Dutta R. This is an open access article distributed under the Creative Huntington’s disease (HD) is an incurable neurodegenerative disease that causes involuntary Commons Attribution License, which permits movements, emotional lability, and cognitive dysfunction. HD symptoms usually develop between unrestricted use, distribution, and reproduction ages 30 and 50, but can appear as early as 2 or as late as 80 years. Currently no neuroprotective in any medium, provided the original work is and neurorestorative interventions are available. Early multimodal intervention in HD is only properly cited. possible if the genetic diagnosis is made early. Early intervention in HD is only possible if genetic diagnosis is made at the disease onset or when mild symptoms manifest. Growing evidence and Keywords: Huntington’s disease; Genetic; understanding of HD pathomechanism has led researchers to new therapeutic targets. Here, in Pathogenesis; Therapeutic; Multimodal; this article we will talk about the multimodal treatment strategies and recent advances
    [Show full text]
  • Phospholipase C-Related Catalytically Inactive Protein: a Novel Signaling Molecule for Modulating Fat Metabolism and Energy Expenditure
    Journal of Oral Biosciences 61 (2019) 65e72 Contents lists available at ScienceDirect Journal of Oral Biosciences journal homepage: www.elsevier.com/locate/job Review Phospholipase C-related catalytically inactive protein: A novel signaling molecule for modulating fat metabolism and energy expenditure * Takashi Kanematsu a, b, , Kana Oue a, c, Toshiya Okumura a, Kae Harada a, 1, Yosuke Yamawaki a, 2, Satoshi Asano a, Akiko Mizokami d, Masahiro Irifune c, Masato Hirata e a Department of Cellular and Molecular Pharmacology, Division of Basic Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, 734-8553, Japan b Department of Cell Biology and Pharmacology, Faculty of Dental Science, Kyushu University, Fukuoka, 812-8582, Japan c Department of Dental Anesthesiology, Division of Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, 734- 8553, Japan d OBT Research Center, Faculty of Dental Science, Kyushu University, Fukuoka, 812-8582, Japan e Fukuoka Dental College, Fukuoka, 814-0193, Japan article info abstract Article history: Background: Overweight and obesity are defined as excessive or abnormal fat accumulation in adipose Received 16 March 2019 tissues, and increase the risk of morbidity in many diseases, including hypertension, dyslipidemia, type 2 Received in revised form diabetes, coronary heart disease, and stroke, through pathophysiological mechanisms. There is strong 17 April 2019 evidence that weight loss reduces the risk of metabolic syndrome by limiting blood pressure and Accepted 19 April 2019 improving the levels of serum triglycerides, total cholesterol, low-density lipoprotein-cholesterol, and Available online 15 May 2019 high-density lipoprotein-cholesterol. To date, several attempts have been made to develop effective anti- obesity medication or weight-loss drugs; however, satisfactory drugs for clinical use have not yet been Keywords: Adipose tissue developed.
    [Show full text]
  • Phosphodiesterase (PDE)
    Phosphodiesterase (PDE) Phosphodiesterase (PDE) is any enzyme that breaks a phosphodiester bond. Usually, people speaking of phosphodiesterase are referring to cyclic nucleotide phosphodiesterases, which have great clinical significance and are described below. However, there are many other families of phosphodiesterases, including phospholipases C and D, autotaxin, sphingomyelin phosphodiesterase, DNases, RNases, and restriction endonucleases, as well as numerous less-well-characterized small-molecule phosphodiesterases. The cyclic nucleotide phosphodiesterases comprise a group of enzymes that degrade the phosphodiester bond in the second messenger molecules cAMP and cGMP. They regulate the localization, duration, and amplitude of cyclic nucleotide signaling within subcellular domains. PDEs are therefore important regulators ofsignal transduction mediated by these second messenger molecules. www.MedChemExpress.com 1 Phosphodiesterase (PDE) Inhibitors, Activators & Modulators (+)-Medioresinol Di-O-β-D-glucopyranoside (R)-(-)-Rolipram Cat. No.: HY-N8209 ((R)-Rolipram; (-)-Rolipram) Cat. No.: HY-16900A (+)-Medioresinol Di-O-β-D-glucopyranoside is a (R)-(-)-Rolipram is the R-enantiomer of Rolipram. lignan glucoside with strong inhibitory activity Rolipram is a selective inhibitor of of 3', 5'-cyclic monophosphate (cyclic AMP) phosphodiesterases PDE4 with IC50 of 3 nM, 130 nM phosphodiesterase. and 240 nM for PDE4A, PDE4B, and PDE4D, respectively. Purity: >98% Purity: 99.91% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 10 mM × 1 mL, 10 mg, 50 mg (R)-DNMDP (S)-(+)-Rolipram Cat. No.: HY-122751 ((+)-Rolipram; (S)-Rolipram) Cat. No.: HY-B0392 (R)-DNMDP is a potent and selective cancer cell (S)-(+)-Rolipram ((+)-Rolipram) is a cyclic cytotoxic agent. (R)-DNMDP, the R-form of DNMDP, AMP(cAMP)-specific phosphodiesterase (PDE) binds PDE3A directly.
    [Show full text]
  • Hypomethylation-Linked Activation of PLCE1 Impedes Autophagy and Promotes Tumorigenesis Through MDM2-Mediated Ubiquitination and Destabilization of P53
    Author Manuscript Published OnlineFirst on February 17, 2020; DOI: 10.1158/0008-5472.CAN-19-1912 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Hypomethylation-linked activation of PLCE1 impedes autophagy and promotes tumorigenesis through MDM2-mediated ubiquitination and destabilization of p53 Yunzhao Chen1,3*, Huahua Xin1*, Hao Peng1*, Qi Shi1, Menglu Li1, Jie Yu3, Yanxia Tian1, Xueping Han1, Xi Chen1, Yi Zheng4, Jun Li5, Zhihao Yang1, Lan Yang1, Jianming Hu1, Xuan Huang2, Zheng Liu2, Xiaoxi Huang2, Hong Zhou6, Xiaobin Cui1**, Feng Li1,2** 1 Department of Pathology and Key Laboratory for Xinjiang Endemic and Ethnic Diseases, The First Affiliated Hospital, Shihezi University School of Medicine, Shihezi 832002, China; 2 Department of Pathology and Medical Research Center, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China; 3 The people's hospital of Suzhou National Hi-Tech District, Suzhou 215010, China; 4 Department of Gastroenterology, The First Affiliated Hospital, Shihezi University School of Medicine, Shihezi 832002, China; 5 Department of Ultrasound, The First Affiliated Hospital, Shihezi University School of Medicine, Shihezi 832002, China; 6 Bone Research Program, ANZAC Research Institute, The University of Sydney, Sydney, Australia. Running title: PLCE1 impedes autophagy via MDM2-p53 axis in ESCC *These authors contributed equally to this work. Corresponding authors: **Xiaobin Cui, Department of Pathology and Key Laboratory for Xinjiang Endemic and Ethnic Diseases, The First Affiliated Hospital, Shihezi University School of Medicine, Shihezi 832002, China. Phone: 86.0377.2850955; E-mail: [email protected]; **Feng Li, Department of Pathology and Medical Research Center, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China.
    [Show full text]
  • Stimulation of Phospholipid Metabolism in Embryonic Muscle
    Proc. Natl. Acad. Sci. USA Vol. 76, No. 9, pp. 4474-4478, September 1979 Cell Biology Stimulation of phospholipid metabolism in embryonic muscle cells treated with phospholipase C (phospholipid synthesis/myogenesis) CLAUDIA KENT Department of Biochemistry, Purdue University, West Lafayette, Indiana 47907 Communicated by Edwin T. Mertz, May 29, 1979 ABSTRACT Phospholipid metabolism is dramatically MATERIALS AND METHODS stimulated in cultured myogenic cells in which cell fusion was inhibited with phospholipase C (phosphatidylcholine choline- Cultured Cells. Pectoral muscle from 11-day chicken em- phosphohydrolase; EC 3.1.4.3). Phospholipase C was active bryos was dissected, loose connective tissue was removed, and under the culture conditions as shown by the degradation of the muscle was minced into 1- to 2-mm fragments. Cells were exogenous phosphatidylcholine. Rates of incorporation of 32p; dissociated from the tissue fragments by trituration with a and [metkyl-3Hlcholine into lipids were about 5-fold greater in phospholipase-treated cells than in either untreated fusing cells pasteur pipette (8) in calcium- and magnesium-free Earle's salt or untreated cells prevented from fusing by-calcium deprivation. solution. The cell suspension was filtered through cheesecloth, The greatest stimulation in the phospholipase C-treated cultures preplated for 15 min (9), and then diluted with culture medium occurred with synthesis of phospai tlcholine and sphin- to 5 X 105 cells/ml. The cells were plated in tissue culture dishes gomyelin; synthesis of phosphatidyinositol and cardiolipin was precoated with rat tail collagen (10) at 8 ml of cell suspension not stimulated. Degradation of cellular [32Plphosphatidylcholine and appearance in the culture medium of the degradation per 100 mm dish.
    [Show full text]
  • Challenges on Cyclic Nucleotide Phosphodiesterases Imaging with Positron Emission Tomography: Novel Radioligands and (Pre-)Clinical Insights Since 2016
    International Journal of Molecular Sciences Review Challenges on Cyclic Nucleotide Phosphodiesterases Imaging with Positron Emission Tomography: Novel Radioligands and (Pre-)Clinical Insights since 2016 Susann Schröder 1,2,* , Matthias Scheunemann 2, Barbara Wenzel 2 and Peter Brust 2 1 Department of Research and Development, ROTOP Pharmaka Ltd., 01328 Dresden, Germany 2 Department of Neuroradiopharmaceuticals, Institute of Radiopharmaceutical Cancer Research, Research Site Leipzig, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), 04318 Leipzig, Germany; [email protected] (M.S.); [email protected] (B.W.); [email protected] (P.B.) * Correspondence: [email protected]; Tel.: +49-341-234-179-4631 Abstract: Cyclic nucleotide phosphodiesterases (PDEs) represent one of the key targets in the research field of intracellular signaling related to the second messenger molecules cyclic adenosine monophosphate (cAMP) and/or cyclic guanosine monophosphate (cGMP). Hence, non-invasive imaging of this enzyme class by positron emission tomography (PET) using appropriate isoform- selective PDE radioligands is gaining importance. This methodology enables the in vivo diagnosis and staging of numerous diseases associated with altered PDE density or activity in the periphery and the central nervous system as well as the translational evaluation of novel PDE inhibitors as therapeutics. In this follow-up review, we summarize the efforts in the development of novel PDE radioligands and highlight (pre-)clinical insights from PET studies using already known PDE Citation: Schröder, S.; Scheunemann, radioligands since 2016. M.; Wenzel, B.; Brust, P. Challenges on Cyclic Nucleotide Keywords: positron emission tomography; cyclic nucleotide phosphodiesterases; PDE inhibitors; Phosphodiesterases Imaging with PDE radioligands; radiochemistry; imaging; recent (pre-)clinical insights Positron Emission Tomography: Novel Radioligands and (Pre-)Clinical Insights since 2016.
    [Show full text]
  • Hypomethylation-Linked Activation of PLCE1 Impedes
    Published OnlineFirst February 17, 2020; DOI: 10.1158/0008-5472.CAN-19-1912 CANCER RESEARCH | MOLECULAR CELL BIOLOGY Hypomethylation-Linked Activation of PLCE1 Impedes Autophagy and Promotes Tumorigenesis through MDM2-Mediated Ubiquitination and Destabilization of p53 Yunzhao Chen1,2, Huahua Xin1, Hao Peng1, Qi Shi1, Menglu Li1,JieYu2, Yanxia Tian1, Xueping Han1, Xi Chen1, Yi Zheng3,JunLi4, Zhihao Yang1, Lan Yang1, Jianming Hu1, Xuan Huang5, Zheng Liu5, Xiaoxi Huang5, Hong Zhou6, Xiaobin Cui1, and Feng Li1,5 ABSTRACT ◥ Esophageal squamous cell carcinoma (ESCC) is one of the dead- Significance: These findings identify hypomethylation- liest malignant diseases. Multiple studies with large clinic-based mediated activation of PLCE1 as a potential oncogene that cohorts have revealed that variations of phospholipase C epsilon 1 blocks cellular autophagy of esophageal carcinoma by facilitat- (PLCE1) correlate with esophageal cancer susceptibility. However, ing the MDM2-dependent ubiquitination of p53 and subsequent the causative role of PLCE1 in ESCC has remained elusive. Here, we degradation. observed that hypomethylation-mediated upregulation of PLCE1 Graphical Abstract: http://cancerres.aacrjournals.org/content/ expression was implicated in esophageal carcinogenesis and poor canres/80/11/2175/F1.large.jpg. prognosis in ESCC cohorts. PLCE1 inhibited cell autophagy and suppressed the protein expression of p53 and various p53-targeted genes in ESCC. Moreover, PLCE1 decreased the half-life of p53 and Normal cells Cancer cells promoted p53 ubiquitination, whereas it increased the half-life of PLCE1 Cytoplasm Cytoplasm mouse double minute 2 homolog (MDM2) and inhibited its ubiqui- wtp53 wtp53 tination, leading to MDM2 stabilization. Mechanistically, the func- MDM2 MDM2 wtp53 MDM2 MDM2 Nucleus tion of PLCE1 correlated with its direct binding to both p53 and Nucleus wtp53 Ub Ub MDM2, which promoted MDM2-dependent ubiquitination of p53 PLCE1 MDM2 wtp53 Ub wtp53 wtp53 and subsequent degradation in vitro.
    [Show full text]
  • Juvenile Hormone-Activated Phospholipase C Pathway PNAS PLUS Enhances Transcriptional Activation by the Methoprene-Tolerant Protein
    Juvenile hormone-activated phospholipase C pathway PNAS PLUS enhances transcriptional activation by the methoprene-tolerant protein Pengcheng Liua, Hong-Juan Pengb, and Jinsong Zhua,1 aDepartment of Biochemistry, Virginia Polytechnic Institute and State University, Blacksburg, VA 24061; and bDepartment of Pathogen Biology, School of Public Health and Tropical Medicine, Southern Medical University, Guangzhou, Guangdong, 510515, China Edited by Lynn M. Riddiford, Howard Hughes Medical Institute Janelia Farm Research Campus, Ashburn, VA, and approved March 11, 2015 (received for review December 4, 2014) Juvenile hormone (JH) is a key regulator of a wide diversity of in the regulatory regions of JH-responsive genes, leading to developmental and physiological events in insects. Although the the transcriptional activation of these genes (12). This function intracellular JH receptor methoprene-tolerant protein (MET) func- of MET–TAI in the JH-induced gene expression seems to be tions in the nucleus as a transcriptional activator for specific JH- evolutionarily conserved in Ae. aegypti, D. melanogaster, the red regulated genes, some JH responses are mediated by signaling flour beetle Tribolium castaneum, the silkworm Bombyx mori,and pathways that are initiated by proteins associated with plasma the cockroach Bombyx mori (9, 13–16). membrane. It is unknown whether the JH-regulated gene expres- The mechanisms by which JH exerts pleiotropic functions are sion depends on the membrane-mediated signal transduction. In manifold in insects. Several studies suggest that JH can act via a Aedes aegypti mosquitoes, we found that JH activated the phos- receptor on plasma membrane (3, 17). For example, develop- pholipase C (PLC) pathway and quickly increased the levels of ino- ment of ovarian patency during vitellogenesis is stimulated by JH sitol 1,4,5-trisphosphate, diacylglycerol, and intracellular calcium, in some insects via transmembrane signaling cascades that in- leading to activation and autophosphorylation of calcium/calmod- volve second messengers (18, 19).
    [Show full text]
  • Dopamine Response Gene Pathways in Dorsal Striatum Msns from a Gene Expression Viewpoint: Camp‑Mediated Gene Networks Vladimir N
    Babenko et al. BMC Neurosci (2020) 21:12 https://doi.org/10.1186/s12868-020-00560-w BMC Neuroscience RESEARCH ARTICLE Open Access Dopamine response gene pathways in dorsal striatum MSNs from a gene expression viewpoint: cAMP-mediated gene networks Vladimir N. Babenko1,2*, Anna G. Galyamina1, Igor B. Rogozin3, Dmitry A. Smagin1 and Natalia N. Kudryavtseva1 Abstract Background: Medium spiny neurons (MSNs) comprise the main body (95% in mouse) of the dorsal striatum neu- rons and represent dopaminoceptive GABAergic neurons. The cAMP (cyclic Adenosine MonoPhosphate)—mediated cascade of excitation and inhibition responses observed in MSN intracellular signal transduction is crucial for neuro- science research due to its involvement in the motor and behavioral functions. In particular, all types of addictions are related to MSNs. Shedding the light on the mechanics of the above-mentioned cascade is of primary importance for this research domain. Results: A mouse model of chronic social conficts in daily agonistic interactions was used to analyze dorsal stria- tum neurons genes implicated in cAMP-mediated phosphorylation activation pathways specifc for MSNs. Based on expression correlation analysis, we succeeded in dissecting Drd1- and Drd2-dopaminoceptive neurons (D1 and D2, correspondingly) gene pathways. We also found that D1 neurons genes clustering are split into two oppositely cor- related states, passive and active ones, the latter apparently corresponding to D1 fring stage upon protein kinase A (PKA) activation. We observed that under defeat stress in chronic social conficts the loser mice manifest overall depression of dopa- mine-mediated MSNs activity resulting in previously reported reduced motor activity, while the aggressive mice with positive fghting experience (aggressive mice) feature an increase in both D1-active phase and D2 MSNs genes expression leading to hyperactive behavior pattern corresponded by us before.
    [Show full text]
  • The MMAC1 Tumor Suppressor Phosphatase Inhibits Phospholipase C and Integrin-Linked Kinase Activity
    Oncogene (2000) 19, 200 ± 209 ã 2000 Macmillan Publishers Ltd All rights reserved 0950 ± 9232/00 $15.00 www.nature.com/onc The MMAC1 tumor suppressor phosphatase inhibits phospholipase C and integrin-linked kinase activity Alyssa M Morimoto1, Michael G Tomlinson1, Kaname Nakatani2, Joseph B Bolen3, Richard A Roth2 and Ronald Herbst*,1 1Department of Cell Signaling, DNAX Research Institute, 901 California Ave, Palo Alto, California, CA 94304, USA; 2Department of Molecular Pharmacology, Stanford University School of Medicine, Stanford, California, CA 94305, USA; 3Department of Oncology, Hoechst Marion Roussel, Bridgewater, New Jersey, NJ 08807, USA Loss of the tumor suppressor MMAC1 has been shown Introduction to be involved in breast, prostate and brain cancer. Consistent with its identi®cation as a tumor suppressor, MMAC1 (also known as PTEN or TEP-1) is mutated at expression of MMAC1 has been demonstrated to reduce a high frequency in brain, breast, and prostate tumors cell proliferation, tumorigenicity, and motility as well as as well as in melanomas and endometrial carcinomas, aect cell±cell and cell±matrix interactions of malignant (Guldberg et al., 1997; Kong et al., 1997; Li and Sun, human glioma cells. Subsequently, MMAC1 was shown 1997; Li et al., 1997; Steck et al., 1997). These to have lipid phosphatase activity towards PIP3 and observations suggest that MMAC1 acts as a tumor protein phosphatase activity against focal adhesion suppressor in multiple tissues. Indeed, subsequent kinase (FAK). The lipid phosphatase activity of studies showed that reintroduction of this gene into MMAC1 results in decreased activation of the PIP3- human glioma cells reduced cell growth, tumorigenicity dependent, anti-apoptotic kinase, AKT.
    [Show full text]
  • (PLCE1) Polymorphisms and Colorectal Cancer Risk in a Chinese Han Population: a Case-Control Study
    Int J Clin Exp Med 2015;8(10):19360-19366 www.ijcem.com /ISSN:1940-5901/IJCEM0014401 Original Article The association between phospholipase C epsilon gene (PLCE1) polymorphisms and colorectal cancer risk in a Chinese Han population: a case-control study Yongwang Zhang1*, Yanwei Gong2*, Shuli Du3, Mengdan Yan3, Tingting Geng3,4, Tian Feng3, Jianrui Wang5, Tianbo Jin3,6 1Department of General Surgery, Yulin First Hospital, Yulin 718000, China; 2Department of the Medical Section, Yulin First Hospital, Yulin 718000, China; 3National Engineering Research Center for Miniaturized Detection Systems, Xi’an 710069, Shaanxi, China; 4Department of Endocrinology, The First Affiliated Hospital of Xi’an Jiaotong University School of Medicine, Xi’an 710061, Shaanxi, China; 5First Department of General Surgery, The Fourth Hospital of Yulin, Yulin 719000, China; 6School of Life Sciences, Northwest University, Xi’an 710069, China. *Equal contributors. Received August 12, 2015; Accepted October 10, 2015; Epub October 15, 2015; Published October 30, 2015 Abstract: Background: Heritable factors contribute to the development of colorectal cancer (CRC). We investigated the association between single nucleotide polymorphisms in phospholipase C epsilon 1 (PLCE1) and CRC suscep- tibility. Methods: We selected eight tag single nucleotide polymorphisms (tSNPs) and investigated whether they were associated with CRC in Chinese Han population. In this study, we used Sequenom MassARRAY technology and genotyped 276 CRC cases and 385 controls. The effects of the polymorphisms on the risk of CRC were expressed as odds ratios (ORs) with 95% confidence intervals (95% CIs), evaluated by different genetic models using uncondi- tional logistic regression analysis adjusted for age and gender. We also analyzed the risk of the eight PLCE1 tSNPs in different histology of CRC.
    [Show full text]
  • Dual Activation of Phosphodiesterase 3 and 4 Regulates Basal Cardiac Pacemaker Function and Beyond
    International Journal of Molecular Sciences Review Dual Activation of Phosphodiesterase 3 and 4 Regulates Basal Cardiac Pacemaker Function and Beyond Tatiana M. Vinogradova * and Edward G. Lakatta Laboratory of Cardiovascular Science, Intramural Research Program, National Institute on Aging, National Institute of Health, 251 Bayview Boulevard, Baltimore, MD 21224, USA; [email protected] * Correspondence: [email protected] Abstract: The sinoatrial (SA) node is the physiological pacemaker of the heart, and resting heart rate in humans is a well-known risk factor for cardiovascular disease and mortality. Consequently, the mechanisms of initiating and regulating the normal spontaneous SA node beating rate are of vital importance. Spontaneous firing of the SA node is generated within sinoatrial nodal cells (SANC), which is regulated by the coupled-clock pacemaker system. Normal spontaneous beating of SANC is driven by a high level of cAMP-mediated PKA-dependent protein phosphorylation, which rely on the balance between high basal cAMP production by adenylyl cyclases and high basal cAMP degradation by cyclic nucleotide phosphodiesterases (PDEs). This diverse class of enzymes includes 11 families and PDE3 and PDE4 families dominate in both the SA node and cardiac myocardium, degrading cAMP and, consequently, regulating basal cardiac pacemaker function and excitation-contraction coupling. In this review, we will demonstrate similarities between expression, distribution, and colocalization of various PDE subtypes in SANC and cardiac myocytes of different species, including humans, focusing on PDE3 and PDE4. Here, we will describe specific targets of the coupled-clock pacemaker system modulated by dual PDE3 + PDE4 activation and provide Citation: Vinogradova, T.M.; Lakatta, evidence that concurrent activation of PDE3 + PDE4, operating in a synergistic manner, regulates the E.G.
    [Show full text]